Tri Locum Partners LP
In its 13F for Q1 2024 (holdings as of March 31, 2024, filed May 15, 2024), Tri Locum Partners LP reported 27 stock positions worth $288.4 million. Its top holding was Teva Pharmaceutical-SP ADR (TEVA) at 10.8% of the portfolio, followed by Avadel Pharmaceuticals plc (AVDL, 7.0%) and Silk Road Medical (SILK, 6.9%). Compared with Q4 2023, it opened 13 new positions, sold out of 9, added to 8 and reduced 6. The biggest buy was a new position in Silk Road Medical (SILK) and the biggest sale an exit from Abbvie (ABBV).
- Most Recent 13F
- Q2 2026
- Location
- NEW YORK, NY
- CIK
- 0001826434
- Portfolio Value
- $288.4M (Q1 2024)
- SEC Filing
- 0001826434-24-000004 ↗ filed May 15, 2024
Holdings Value
Holdings 27 stocks · $288.4M
| TEVA Teva Pharmaceutical-SP ADR | 10.84% | 2,216,188 | $31.3M | Add +23.5% |
| AVDL Avadel Pharmaceuticals plc | 6.97% | 1,189,511 | $20.1M | Add +41.6% |
| SILK Silk Road Medical Inc. filed as SILK RD MED INC | 6.88% | 1,083,605 | $19.9M | New |
| NTRA Natera Inc. | 6.03% | 190,114 | $17.4M | Add +34.0% |
| ASND Ascendis Pharma A/S | 5.91% | 112,670 | $17.0M | Add +13.2% |
| LEGN Legend Biotech Corp.-ADR | 5.52% | 283,773 | $15.9M | Add +177.6% |
| MRK Merck & Co. Inc. | 5.45% | 119,200 | $15.7M | New |
| VRTX Vertex Pharmaceuticals Inc. | 5.16% | 35,598 | $14.9M | New |
| MDGL Madrigal Pharmaceuticals Inc. | 4.94% | 53,355 | $14.2M | Add +109.0% |
| BAX Baxter International Inc. | 4.71% | 317,566 | $13.6M | New |
| MRUS Merus NV | 4.47% | 286,322 | $12.9M | New |
| TNDM Tandem Diabetes Care Inc. | 4.01% | 326,506 | $11.6M | New |
| ARGX Argenx SE - ADR | 3.82% | 27,981 | $11.0M | Add +15.7% |
| XENE Xenon Pharmaceuticals Inc. | 3.10% | 207,465 | $8.9M | Reduce -8.0% |
| REGN Regeneron Pharmaceuticals | 2.86% | 8,567 | $8.2M | Reduce -46.5% |
| AXSM Axsome Therapeutics Inc. | 2.84% | 102,711 | $8.2M | Reduce -21.4% |
| PRAX Praxis Precision Medicines I | 2.25% | 106,494 | $6.5M | Reduce -57.2% |
| EXAS Exact Sciences Corp. | 2.16% | 90,000 | $6.2M | New |
| LYRA Lyra Therapeutics Inc. | 2.11% | 978,793 | $6.1M | New |
| ATXS Astria Therapeutics Inc. | 1.80% | 369,549 | $5.2M | Reduce -31.9% |
| INSP Inspire Medical Systems Inc. | 1.76% | 23,566 | $5.1M | New |
| ALPN Alpine Immune Sciences Inc. | 1.66% | 120,687 | $4.8M | New |
| ARCT Arcturus Therapeutics Holdin | 1.63% | 138,927 | $4.7M | Add +25.8% |
| ARQT Arcutis Biotherapeutics Inc. | 1.55% | 449,694 | $4.5M | New |
| MIND MEDICINE MINDMED INC | 1.24% | 379,596 | $3.6M | New |
| CATX Perspective Therapeutics Inc. | 0.32% | 780,303 | $929K | New |
| FEMY Femasys Inc. | 0.02% | 30,606 | $47K | Reduce -15.3% |
Portfolio Sells Q4 2023 → Q1 2024
| ABBV Abbvie Inc. | Sold out | 0.00% | −12.77 |
| GEHC GE Healthcare Technology | Sold out | 0.00% | −6.52 |
| BIIB Biogen Inc. | Sold out | 0.00% | −5.82 |
| CTLT Catalent Inc. | Sold out | 0.00% | −5.77 |
| REGN Regeneron Pharmaceuticals | Reduce -46.5% | 2.86% | −4.04 |
| VRNA Verona Pharma Ltd. | Sold out | 0.00% | −2.86 |
| AXSM Axsome Therapeutics Inc. | Reduce -21.4% | 2.84% | −2.27 |
| XENE Xenon Pharmaceuticals Inc. | Reduce -8.0% | 3.10% | −2.00 |
| AZN Astrazeneca PLC-Spons ADR | Sold out | 0.00% | −1.94 |
| SRRK Scholar Rock Holding Corp. | Sold out | 0.00% | −1.91 |
| IMTX Immatics NV | Sold out | 0.00% | −1.42 |
| MLTX Moonlake Immunotherapeutics | Sold out | 0.00% | −1.41 |
| PRAX Praxis Precision Medicines I | Reduce -57.2% | 2.25% | −0.47 |
| ATXS Astria Therapeutics Inc. | Reduce -31.9% | 1.80% | −0.24 |
| FEMY Femasys Inc. | Reduce -15.3% | 0.02% | −0.00 |
Portfolio Buys Q4 2023 → Q1 2024
| SILK Silk Road Medical Inc. | New | 6.88% | +6.88 |
| MRK Merck & Co. Inc. | New | 5.45% | +5.45 |
| VRTX Vertex Pharmaceuticals Inc. | New | 5.16% | +5.16 |
| BAX Baxter International Inc. | New | 4.71% | +4.71 |
| MRUS Merus NV | New | 4.47% | +4.47 |
| TNDM Tandem Diabetes Care Inc. | New | 4.01% | +4.01 |
| LEGN Legend Biotech Corp.-ADR | Add +177.6% | 5.52% | +2.50 |
| EXAS Exact Sciences Corp. | New | 2.16% | +2.16 |
| LYRA Lyra Therapeutics Inc. | New | 2.11% | +2.11 |
| MDGL Madrigal Pharmaceuticals Inc. | Add +109.0% | 4.94% | +2.04 |
| INSP Inspire Medical Systems Inc. | New | 1.76% | +1.76 |
| NTRA Natera Inc. | Add +34.0% | 6.03% | +1.67 |
| ALPN Alpine Immune Sciences Inc. | New | 1.66% | +1.66 |
| TEVA Teva Pharmaceutical-SP ADR | Add +23.5% | 10.84% | +1.65 |
| ARQT Arcutis Biotherapeutics Inc. | New | 1.55% | +1.55 |
| MIND MEDICINE MINDMED INC | New | 1.24% | +1.24 |
| AVDL Avadel Pharmaceuticals plc | Add +41.6% | 6.97% | +1.15 |
| CATX Perspective Therapeutics Inc. | New | 0.32% | +0.32 |
| ARCT Arcturus Therapeutics Holdin | Add +25.8% | 1.63% | −0.08 |
| ASND Ascendis Pharma A/S | Add +13.2% | 5.91% | −0.25 |
| ARGX Argenx SE - ADR | Add +15.7% | 3.82% | −0.70 |
Options Activity Q4 2023 → Q1 2024
| KVUE Kenvue Inc. | put | Sold out | 698,800 | $15.0Mbefore exit |
Calls and puts are listed by the shares they cover; their value is not part of the stock holdings above.
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 19 | $813.2M | JNJ, VRTX, LLY, ASND, DXCM |
| Q1 2026 | 17 | $712.5M | JNJ, ISRG, TMO, ASND, VRTX |
| Q4 2025 | 15 | $770.1M | JNJ, DHR, LLY, UTHR, ASND |
| Q3 2025 | 18 | $435.1M | JNJ, UTHR, MRK, AXSM, ASND |
| Q2 2025 | 23 | $329.5M | TEVA, MDGL, ALNY, ARGX, ASND |
| Q1 2025 | 22 | $194.9M | CI, MCK, SLNO, TEVA, INSP |
| Q4 2024 | 28 | $482.7M | TEVA, ZBH, ARGX, NTRA, INSP |
| Q3 2024 | 20 | $417.4M | PFE, TEVA, NTRA, STVN, ARGX |
| Q2 2024 | 25 | $395.5M | TEVA, ARGX, ASND, AMGN, NTRA |
| Q1 2024 | 27 | $288.4M | TEVA, AVDL, SILK, NTRA, ASND |